Pharmacists United for Truth and Transparency and member Dave Marley were featured in The New York Times today. Reporter Duff Wilson’s article explains how PBMs and drug manufacturer Pfizer plan to limit the sale of generic Lipitor when the drug hits the market Nov. 30.
Bloomberg News reporter Molly Peterson’s article on blocking generic Lipitor also features the group and member Dave Marley. The piece was reprinted in several newspapers across the country, including the Sarasota Herald-Tribune, and on the financial news websites Businessweek.com and InvestorPlace.com.
From The New York Times:
Objections to the deal were raised publicly on Thursday in a news release from a group called Pharmacists United for Truth and Transparency, which opposes some tactics of pharmacy benefit managers. The statement called the move “a blatant attempt” by benefit managers to keep Pfizer’s discount while employers still have to pay the full price of the brand-name drug.
David Marley, an independent pharmacist in Winston-Salem, N.C., and spokesman for the group, said the benefit companies and Pfizer would profit at a cost to employers, the government and health care overall.
“That’s why this is unique: We’re talking about blocking a truly less expensive drug, which is why the employers have got to be on top of this,” Mr. Marley said. “This is the most aggressive I’ve seen where they are trusting the employer is not going to figure out the whole game.”